Insights

Gathering insights about JUNO…

Similar companies to JUNO

JUNO Tech Stack

JUNO uses 8 technology products and services including Linkedin Ads, Linkedin Insight Tag, HubSpot Analytics, and more. Explore JUNO's tech stack below.

Linkedin Ads
Advertising
Linkedin Insight Tag
Analytics
HubSpot Analytics
Analytics
cdnjs
Content Delivery Network
HubSpot CMS Hub
Content Management System
HubSpot Chat
Live Chat
Open Graph
Miscellaneous
Nginx
Web Servers

Media & News

NTT DATA-led JUNO Submarine Cable Plans to Deploy Ciena's WaveLogic 6 to Boost Network Capacity
TOKYO--(BUSINESS WIRE)--Seren Juno Network Co., Ltd. and Seren Juno Network America Inc (Seren), operator of the NTT DATA-led JUNO submarine cable system, will deploy Ciena's (NYSE: CIEN) GeoMesh Extreme, powered by WaveLogic 6 Extreme (WL6e), to support Japan's digital hub ambitions. Linking the United States and Japan, the 10,000km JUNO cable is estimated to launch at the end of 2024, supporting the delivery of high-capacity services across Asia Pacific. “NTT DATA is dedicated to providing re.
Jun 11, 2024 | www.businesswire.com
Britain's Royal Mint launches coin for 80th anniversary of D-Day landings
LONDON (Reuters) - Britain's Royal Mint has launched a coin marking next month's 80th anniversary of the 1944 D-Day landings, when 150,000 Allied soldiers invaded France to drive out the forces of Nazi Germany. Designed by artist David Lawrence with support from Imperial War Museums, the 50 pence coin, equivalent to around 60 cents, depicts Allied soldiers disembarking onto a beach in Normandy as war planes fly above. It is inscribed with "D-DAY 6 JUNE 1944 UTAH OMAHA GOLD JUNO SWORD", referring to the codenamed beaches where Allied troops landed in history's largest amphibious invasion on June 6, 1944. The portrait of Britain's King Charles is on the other side. "We are proud to unveil this tribute to the courage and resilience of British and Allied troops eight decades ago, which will serve as a permanent reminder of their sacrifices and bravery," Rebecca Morgan, director of commemorative coin at the Royal Mint, said in a statement. As part of its unveiling, French sand artist Jehan-Benjamin Tarain produced a 35-metre (115 ft) diameter depiction of the new coin on Gold Beach in northern France. Together with fellow sand artist Sam Dougados, it took them 5 hours and 30 minutes to create the sand art, the Royal Mint said. ($1 = 0.7875 pounds) (Reporting by Marie-Louise Gumuchian; Editing by Alison Williams)
May 20, 2024 | www.marketscreener.com
Juno Therapeutics to Report Third Quarter 2017 Financial Results on Wednesday, November 1
SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the third quarter 2017 on Wednesday, November 1, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 1:30 p.m. Pacific Time (PT) / 4:30 p.m. Eastern Time (ET). Analysts and investors can participate in the conference call by dialing (855) 780-7198 for domestic callers and (631) 485-4870 for international callers, using the conference ID# 2899809. The webcast can be accessed live on the Investor Relations page of Juno's website, www.JunoTherapeutics.com, and will be available for replay for 30 days following the call. About Juno Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19-directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Juno’s product candidate JCAR017 was developed in collaboration with SCRI and others. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, and business plans, and the anticipated timing of the financial results release and business update. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno’s ability to attract and retain key scientific, quality control/assurance, manufacturing or management personnel; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see the information Juno has included in its periodic reports and other documents filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.
Oct 25, 2017 | www.businesswire.com
Juno Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3
SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the second quarter 2017 on Thursday, August 3, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET). Analysts and investors can participate in the conference call by dialing (855) 780-7198 for domestic callers and (631) 485-4870 for international callers, using the conference ID# 61926954. The webcast can be accessed live on the Investor Relations page of Juno's website, www.JunoTherapeutics.com, and will be available for replay for 30 days following the call. ABOUT JUNO Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19-directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Juno’s product candidate JCAR017 was developed in collaboration with SCRI and others. FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, and business plans, and the anticipated timing of the financial results release and business update. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno’s ability to attract and retain key scientific, quality control/assurance, manufacturing or management personnel; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see Juno's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 4, 2017 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.
Jul 27, 2017 | www.businesswire.com
Juno Therapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4
SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the first quarter 2017 on Thursday, May 4, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET). Analysts and investors can participate in the conference call by dialing (855) 780-7198 for domestic callers and (631) 485-4870 for international callers, using the conference ID# 7603931. The webcast can be accessed live on the Investor Relations page of Juno's website, www.JunoTherapeutics.com, and will be available for replay for 30 days following the call. ABOUT JUNO Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19-directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Juno’s product candidate JCAR017 was developed in collaboration with SCRI and others. FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, and business plans, and the anticipated timing of the financial results release and business update. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see Juno's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2017 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.
Apr 27, 2017 | www.businesswire.com
Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1
SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2016, on Wednesday, March 1, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET). Analysts and investors can participate in the conference call by dialing (855) 780-7198 for domestic callers and (631) 485-4870 for international callers, using the conference ID# 60783648. The webcast can be accessed live on the Investor Relations page of Juno's website, www.JunoTherapeutics.com, and will be available for replay for 30 days following the call. ABOUT JUNO Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19-directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Juno’s product candidate JCAR017 was developed in collaboration with SCRI and others. FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, and business plans, and the anticipated timing of the financial results release and business update. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see Juno's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2016 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.
Feb 22, 2017 | www.businesswire.com
Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold
SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the “ROCKET” trial. The clinical hold was initiated after two patients suffered cerebral edema earlier this week. One patient died and as of last night the other is not expected to recover. Juno has notified the Food & Drug Administration of the voluntary hold and is working with the agency and the Data and Safety Monitoring Board to determine next steps. The company is assessing data from the cases and the trial and is evaluating its options regarding the JCAR015 program. Juno’s trials and plans for its other CD19-directed CAR T cell product candidates, including JCAR017, are not affected. Conference Call Information Juno will host a conference call today to discuss today’s announcement beginning at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET). Analysts and investors can participate in the conference call by dialing (855) 780-7198 for callers in the United States and Canada and +1 (631) 485-4870 for international callers, using the conference ID# 26549311. The webcast can be accessed live on the Investor Relations page of Juno's website, www.JunoTherapeutics.com, and will be available for replay for 30 days following the call. About Juno Juno Therapeutics is building a fully integrated biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno’s long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world’s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, and business plans, Juno’s interactions with the FDA and the Data and Safety Monitoring Board, Juno’s assessments and evaluations, and the impact, if any, on Juno’s trials and plans for its other CD19-directed product candidates. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see Juno's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2016 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.
Nov 23, 2016 | www.businesswire.com

JUNO's Email Address Formats

JUNO uses at least 1 format(s):

JUNO Email Formats	Example	Percentage
First.Last@junolive.com	John.Doe@junolive.com	45%
First@junolive.com	John@junolive.com	5%
First.Last@junolive.com	John.Doe@junolive.com	45%
First@junolive.com	John@junolive.com	5%

Frequently Asked Questions

Where is JUNO's headquarters located?

JUNO's main headquarters is located at Located: Worldwide, US. The company has employees across 2 continents, including North AmericaAsia.

What is JUNO's stock symbol?

JUNO is a publicly traded company; the company's stock symbol is JUNO.

What is JUNO's official website and social media links?

JUNO's official website is junolive.com and has social profiles on LinkedIn.

How much revenue does JUNO generate?

As of October 2023, JUNO's annual revenue reached $15M.

What is JUNO's NAICS code?

JUNO's NAICS code is 5112 - Software Publishers.

How many employees does JUNO have currently?

As of October 2023, JUNO has approximately 51 employees across 2 continents, including North AmericaAsia. Key team members include Head Of Customer Experience: A. A.Head Of Product: E. C.Founder/Ceo Board Member: J. H.. Explore JUNO's employee directory with LeadIQ.

What industry does JUNO belong to?

JUNO operates in the Software Development industry.

What technology does JUNO use?

JUNO's tech stack includes Linkedin AdsLinkedin Insight TagHubSpot AnalyticscdnjsHubSpot CMS HubHubSpot ChatOpen GraphNginx.

What is JUNO's email format?

JUNO's email format typically follows the pattern of . Find more JUNO email formats with LeadIQ.

How much funding has JUNO raised to date?

As of October 2023, JUNO has raised $10M in funding. The last funding round occurred on May 26, 2022 for $10M.

When was JUNO founded?

JUNO was founded in 2020.

JUNO

Software DevelopmentWorldwide, United States51-200 Employees

All your Digital Engagement in one place! JUNO is a Single Destination SaaS Platform for community, events, and learning.
You can:
Increase Value
Increase Revenue &
Increase Loyalty
with ONE digital place for:
--Events, Virtual and Hybrid (Live and On-Demand)
--Community Discussion Forums and Feeds
--Learning Experiences and Certifications
JUNO's software creates transformational experiences and drives results with gamification, human interest modeling, AI, monetization, matchmaking, video streaming, and analytics tools.
You can save time and money on our software, have all your data in one place, break down geographical boundaries, easily pop out content, and promote stronger human connections with your users.

Company Overview

Headquarters: Located: Worldwide, US
Website: junolive.com
Stock Symbol: JUNO
NAICS Code: 5112 - Software Publishers
Founded: 2020
Employees: 51-200

Media & News

Funding & Financials

$10M
JUNO has raised a total of $10M of funding over 2 rounds. Their latest funding round was raised on May 26, 2022 in the amount of $10M.
$10M$50M
JUNO's revenue is in the range of $10M$50M

Funding & Financials

$10M
JUNO has raised a total of $10M of funding over 2 rounds. Their latest funding round was raised on May 26, 2022 in the amount of $10M.
$10M$50M
JUNO's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to JUNO

Moven

Chime

ONE

VARO

Zero

SoFi

Dave

Revolut

Empower

MoneyLion

OXYGEN

N26

SIMPLE

JUNO Tech Stack

Media & News

NTT DATA-led JUNO Submarine Cable Plans to Deploy Ciena's WaveLogic 6 to Boost Network Capacity

Britain's Royal Mint launches coin for 80th anniversary of D-Day landings

Juno Therapeutics to Report Third Quarter 2017 Financial Results on Wednesday, November 1

Juno Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3

Juno Therapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4

Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1

Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold

JUNO's Email Address Formats

Frequently Asked Questions

Where is JUNO's headquarters located?

What is JUNO's stock symbol?

What is JUNO's official website and social media links?

How much revenue does JUNO generate?

What is JUNO's NAICS code?

How many employees does JUNO have currently?

What industry does JUNO belong to?

What technology does JUNO use?

What is JUNO's email format?

How much funding has JUNO raised to date?

When was JUNO founded?

JUNO

Company Overview

Media & News

NTT DATA-led JUNO Submarine Cable Plans to Deploy Ciena's WaveLogic 6 to Boost Network Capacity

Britain's Royal Mint launches coin for 80th anniversary of D-Day landings

Juno Therapeutics to Report Third Quarter 2017 Financial Results on Wednesday, November 1

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?